Medical Microinstruments (MMI)

Attachments

*The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe.
*This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair
2018: Medical Microinstruments S.p.A. Announces €20M in Series A Funding to Advance Its Robotic Platform for Microsurgery
2020: Symani Microsurgical System Cleared in Europe
2026: MMI gets FDA green light to expand study of surgical robot in Alzheimer’s
2026: MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar Capital, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.
2026: MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study
2026: Symani is the only commercially available robotic platform designed specifically for high-precision microsurgical and supermicrosurgical procedures.
Founded 2015
It offers the surgeon motion scaling and tremor elimination and aims to facilitate existing procedures as well as enable new ones in the domain of microsurgery, from post-oncological and trauma reconstructions to ophthalmology, organ transplantation and pediatric surgery.
Mark Toland, CEO of MMI (2026)
MMI has developed the first teleoperated robotic platform for suturing in open surgery with wristed microinstruments.
Pisa, Italy